mani
survivor
outbreak
sever
acut
respiratori
syndrom
sar
develop
residu
pulmonari
fibrosi
increas
sever
seen
older
patient
autopsi
patient
die
sar
also
show
fibrosi
vari
extent
pulmonari
fibrosi
occasion
seen
consequ
sever
respiratori
viral
infect
much
common
sar
coronaviru
sarscov
infect
given
threat
futur
outbreak
sever
coronaviru
diseas
includ
middl
east
respiratori
syndrom
mer
import
understand
mechan
respons
pulmonari
fibrosi
support
develop
therapeut
countermeasur
mitig
sequela
infect
articl
summar
pulmonari
fibrot
chang
observ
sarscov
infect
discuss
extent
respiratori
virus
induc
fibrosi
describ
avail
anim
model
studi
develop
sarscov
induc
fibrosi
review
evid
pulmonari
fibrosi
caus
hyperact
host
respons
lung
injuri
mediat
epiderm
growth
factor
receptor
egfr
signal
summar
work
group
other
indic
inhibit
egfr
signal
may
prevent
excess
fibrot
respons
sarscov
respiratori
viral
infect
propos
direct
futur
research
follow
epidem
sever
acut
respiratori
syndrom
sar
notic
mani
patient
surviv
sever
ill
develop
residu
pulmonari
fibrosi
shown
clinic
find
radiographi
vari
degre
fibrosi
also
observ
autopsi
fatal
case
although
pulmonari
fibrot
chang
occasion
observ
sequela
respiratori
viral
infect
appear
common
follow
sar
coronaviru
sarscov
infect
given
threat
futur
outbreak
sever
coronaviru
diseas
includ
middl
east
respiratori
syndrom
mer
import
understand
mechan
respons
pulmonari
fibrosi
support
develop
therapeut
countermeasur
mitig
sequela
infect
articl
summar
observ
pulmonari
fibrosi
sar
epidem
note
extent
fibrosi
occur
pulmonari
viral
infect
describ
effort
recapitul
fibrot
chang
mous
model
sar
review
evid
condit
repres
hyperact
respons
lung
injuri
driven
proinflammatori
mediat
act
epiderm
growth
factor
receptor
egfr
signal
summar
work
group
other
indic
inhibitor
egfr
may
use
prevent
excess
fibrot
respons
sar
respiratori
viral
infect
indic
direct
futur
research
sever
acut
respiratori
syndrom
coronaviru
sarscov
highli
pathogen
respiratori
viru
sar
patient
initi
present
mild
diseas
often
consist
persist
high
fever
chill
malais
myalgia
headach
dri
cough
progress
sever
follow
week
ill
last
week
patient
resolv
infect
howev
onethird
develop
sever
pulmonari
complic
lead
acut
lung
injuri
acut
respiratori
distress
syndrom
ard
result
intub
prolong
hospit
tsui
et
al
acut
phase
sar
lung
damag
result
edema
bronchiolar
slough
ciliat
epitheli
cell
deposit
hyalinerich
deposit
alveolar
membran
result
reduc
ga
exchang
next
phase
infect
week
lung
display
sign
fibrosi
epitheli
cell
alveolar
space
show
fibrin
deposit
infiltr
inflammatori
cell
fibroblast
final
stage
week
pulmonari
tissu
becom
fibrot
collagen
deposit
cellular
prolifer
seen
alveoli
interstiti
space
cheung
et
al
gu
korteweg
ketai
et
al
radiograph
featur
patient
lung
vari
greatli
individu
howev
characterist
featur
present
patient
includ
progress
unilater
focal
airspac
opac
multifoc
bilater
consolid
later
phase
diseas
comput
tomographi
ct
patient
reveal
consolid
interstiti
thicken
predominantli
peripher
lower
lobe
lung
peiri
et
al
multipl
autopsi
studi
show
diffus
alveolar
damag
dad
hyalin
membran
format
interstiti
thicken
common
featur
sarscov
infect
lung
dad
occur
trauma
injuri
alveolar
bronchiolar
epitheli
cell
caus
termin
small
airway
plug
fluid
cellular
debri
seen
patholog
examin
radiolog
analys
nichol
et
al
tse
et
al
patient
lack
hyalin
membran
format
acut
fibrin
pneumonia
organ
phase
fibrin
deposit
observ
result
reduc
lung
function
acut
lung
injuri
squamou
metaphasia
multinucl
giant
cell
extens
cellular
prolifer
seen
case
mazzulli
et
al
autopsi
sar
patient
also
show
lung
fibrosi
variou
stage
progress
gu
korteweg
hwang
et
al
tse
et
al
observ
uniqu
sar
common
mani
lung
disord
see
importantli
clinic
find
show
older
sar
patient
increas
risk
fibrosi
extent
fibrosi
correl
sever
durat
ill
hwang
et
al
tse
et
al
sever
studi
conduct
patient
resolv
sarscov
infect
mani
studi
report
increas
incid
fibrosi
patient
even
sarscov
clear
one
studi
patient
show
groundglass
appear
indic
fibrosi
chest
xray
score
highresolut
computer
tomographi
one
month
infect
xie
et
al
fig
groundglass
opacif
lung
describ
region
display
hazi
attenu
signal
ct
imag
without
obscur
normal
bronchial
vascular
structur
differenti
diagnosi
groundglass
opacif
infect
pulmonari
edema
interstiti
thicken
fibrot
deposit
collin
stern
second
studi
look
intermedi
recoveri
period
month
infect
fibrot
featur
includ
abnorm
score
airspac
opac
reticular
shadow
seen
patient
respect
hui
et
al
b
one
year
followup
studi
recov
sar
patient
hong
kong
show
sar
survivor
show
decreas
lung
function
increas
lung
fibrosi
compar
normal
popul
david
hui
et
al
b
followup
studi
shown
similar
result
hui
et
al
b
ngai
et
al
ngai
et
al
molecular
pathway
respons
develop
sarscov
induc
fibrosi
observ
recov
patient
well
understood
gap
knowledg
limit
develop
novel
therapi
target
develop
fibrosi
repurpos
exist
treatment
may
effect
sarscov
induc
fibrosi
infect
nonhuman
primat
small
anim
model
avail
recreat
variou
clinic
aspect
sar
subbarao
robert
among
nonhuman
primat
model
cynomolgu
rhesu
macaqu
african
green
monkey
common
marmoset
produc
differ
level
clinic
sign
diseas
seen
human
subbarao
robert
howev
find
often
consist
due
biolog
variabl
anim
small
anim
model
includ
ferret
syrian
golden
hamster
inbr
mice
ferret
hamster
show
viru
replic
lung
infect
intranas
sarscov
hamster
show
lung
patholog
interstiti
pneumon
pulmonari
consolid
diffus
alveolar
damag
conflict
symptom
report
ferret
subbarao
robert
varieti
mous
model
sarscov
develop
rang
mild
sever
diseas
depend
viral
strain
mous
background
use
sarscov
urbani
strain
use
intranas
infect
balbc
strain
mice
viral
replic
lung
spread
organ
glass
et
al
robert
et
al
subbarao
et
al
infect
found
caus
focal
peribronchiolar
perivascular
inflamm
day
post
infect
day
post
infect
sarscov
urbani
larg
clear
lung
minim
effect
weight
loss
clinic
symptom
infect
lung
patholog
time
period
minim
well
outsid
denud
bronchi
around
day
post
infect
minim
appar
peribronchiolar
perivascular
interstiti
inflamm
note
infect
sarscov
strain
signific
weight
loss
clinic
diseas
lung
patholog
creat
blind
passag
sarscov
urbani
adult
balbc
mice
mouseadapt
strain
sarscov
call
passag
mortal
produc
emerg
produc
sever
diseas
death
young
old
balbc
mice
robert
et
al
viru
carri
mutat
genom
replicas
protein
structur
protein
contrast
sarscov
urbani
parent
strain
pulmonari
patholog
mice
infect
viru
show
rapid
progress
inflammatori
chang
extens
damag
bronchiolar
alveolar
epitheli
cell
intracellular
antigen
highli
preval
bronchiolar
epithelium
alveolar
pneumocyt
necrot
debri
observ
within
alveoli
bronchiol
lumen
mice
robert
et
al
strain
sarscov
prove
invalu
tool
understand
host
pathogen
interact
mous
model
sever
knockout
strain
mice
infect
identifi
immun
factor
critic
protect
sarscov
pathogenesi
studi
innat
immun
respons
sarscov
infect
result
increas
pulmonari
inflamm
tissu
damag
greater
mortal
day
postinfect
addit
mice
significantli
higher
sarscov
viral
load
lung
tissu
throughout
cours
infect
demonstr
critic
role
innat
immun
signal
pathway
clearanc
protect
sarscov
sheahan
et
al
addit
signal
trif
adapt
protein
shown
regul
sarscov
pathogenesi
well
show
delet
either
critic
innat
immun
signal
molecul
led
sever
diseas
totura
et
al
recent
use
system
biolog
approach
combin
pathogenesi
transcript
profil
identifi
urokinas
pathway
key
node
control
lung
damag
fibrin
deposit
sarscov
infect
gralinski
et
al
experi
regul
deposit
fibrin
lung
damag
shown
regulatori
control
lung
pathogenesi
mous
model
sarscov
hogan
et
al
show
mice
defici
interferonactiv
transcript
factor
signal
transduc
activ
transcript
much
suscept
pathogenesi
caus
sarscov
hogan
et
al
author
attribut
find
role
interferon
signal
howev
shown
type
ii
iii
interferon
pathway
larg
dispens
protect
sarscov
infect
mice
delet
type
ifn
receptor
type
ii
ifn
receptor
treat
ifn
lambda
neutral
antibodi
display
diseas
compar
seen
wildtyp
mice
still
permiss
sarscov
display
weight
loss
first
day
infect
howev
proceed
regain
weight
abl
reduc
level
viru
lung
day
post
infect
knockout
mice
show
higher
propens
develop
fibrot
lesion
compar
wildtyp
wt
mice
sarscov
infect
show
increas
pathogenesi
even
sarscov
clear
lung
fig
transcriptom
analysi
sarscov
infect
mous
lung
show
knockout
mice
develop
bia
immun
respons
zornetz
et
al
bia
result
higher
number
subtyp
macrophag
lung
call
altern
activ
macrophag
aam
turn
caus
overact
wound
heal
environ
induc
pulmonari
fibrosi
aam
normal
involv
clear
cell
debri
damag
tissu
injuri
gordon
howev
studi
describ
page
et
al
aam
persist
lung
mice
becom
hyperactiv
lead
increas
fibrosi
similar
seen
bleomycin
induc
fibrosi
model
develop
higher
rate
fibrosi
bleomycin
treatment
walter
et
al
summar
advers
pathogen
effect
sarscov
seen
human
patient
model
mice
fibrosi
evid
mice
overprolifer
fibroblast
enhanc
inflammatori
respons
infect
signal
pathway
result
upstream
downstream
cell
type
respons
host
respons
sarscov
seen
human
still
unknown
induct
fibrosi
uniqu
sarscov
recent
metaanalysi
global
idiopath
pulmonari
fibrosi
ipf
rate
find
year
onward
conserv
incid
rang
case
per
per
year
europ
north
america
hutchinson
et
al
case
patient
suffer
ipf
known
trigger
onset
diseas
viral
infect
thought
cofactor
naik
moor
vannella
moor
herpesvirus
epsteinbarr
viru
ebv
human
cytomegaloviru
hcmv
adenoviru
transfusiontransmit
viru
ttv
also
known
torqu
teno
viru
hepat
c
viru
hcv
associ
ipf
diseas
detect
antibodi
viral
protein
viral
gene
product
lung
ipf
patient
naik
moor
elev
serum
level
chemokin
transform
growth
factor
beta
develop
pulmonari
fibrosi
also
report
influenza
virusinfect
patient
wen
et
al
irrespect
etiolog
pulmonari
fibrosi
shown
develop
appar
recoveri
infect
studi
correl
presenc
viru
ipf
unclear
virus
directli
trigger
diseas
creat
condit
requir
develop
pulmonari
fibrosi
caus
secondari
trigger
eg
toxin
particul
radiat
naik
moor
wynn
ramalingam
suggest
pathway
induc
sarscov
infect
lead
observ
pulmonari
fibrosi
may
share
irrespect
damag
induc
factor
human
acut
viral
infect
often
lead
develop
acut
respiratori
distress
syndrom
ard
result
acut
lung
injuri
beigel
et
al
histolog
analysi
show
ard
patient
may
pulmonari
fibrosi
pf
recoveri
martin
et
al
demonstr
mechanist
correl
viral
infect
ard
pf
mous
model
viral
infect
util
anim
studi
produc
addit
evid
virus
trigger
fibrosi
murin
gammaherpesviru
infect
mous
lung
shown
trigger
pulmonari
fibrosi
interferon
ifn
g
receptor
knockout
mice
ifngammar
mora
et
al
addit
antivir
drug
cidofovir
use
post
infect
result
protect
pulmonari
fibrosi
mora
et
al
similar
protect
effect
seen
infect
involv
mutant
defect
reactiv
latenc
suggest
connect
viru
life
cycl
lung
fibrosi
viru
mora
et
al
respiratori
syncyti
viru
rsv
lead
pediatr
respiratori
viru
result
high
morbid
mortal
worldwid
piedimont
perez
rsv
infect
caus
signific
acut
lung
injuri
potenti
ard
pulmonari
complic
piedimont
perez
mous
model
rsv
infect
shown
mous
airway
presensit
ovalbumin
ova
common
model
studi
asthma
immun
respons
lung
infect
mice
much
like
develop
fibrosi
becnel
et
al
anoth
studi
show
rsv
infect
caus
pulmonari
fibrosi
mice
show
enhanc
patholog
combin
cigarett
smoke
foronji
et
al
taken
togeth
data
indic
strong
correl
respiratori
viral
infect
develop
pulmonari
fibrosi
human
anim
model
suggest
viru
infect
either
alon
combin
immun
modul
could
trigger
onset
fibrosi
least
virus
howev
molecular
mechan
follow
viral
infect
ultim
result
fibrosi
larg
remain
unexplor
normal
wound
heal
respons
categor
three
distinct
step
wilson
wynn
first
step
injuri
step
disrupt
epitheli
endotheli
cell
initi
antifibrinolyt
cascad
produc
temporari
patch
wound
second
step
inflamm
step
circul
neutrophil
macrophag
fibrocyt
infiltr
site
injuri
recruit
inflammatori
cell
secret
addit
profibrot
cytokin
tnf
tgfb
macrophag
neutrophil
also
remov
cell
debri
elimin
pathogen
turn
follow
prolifer
differenti
fibroblast
myofibroblast
key
cell
type
coordin
wound
repair
myofibroblast
secret
new
ecm
compon
tissu
rebuilt
wynn
final
third
step
involv
resolut
wound
heal
process
myofibroblast
contract
reduc
size
wound
popul
number
decreas
undergo
apoptosi
analysi
lung
biopsi
sarscov
infect
peopl
show
dysregul
normal
wound
heal
respons
beij
group
nation
research
project
sar
proinflammatori
cytokin
ifng
tnfa
tgfb
found
highli
upregul
serum
sarscov
patient
huang
et
al
wong
et
al
also
found
upregul
mous
model
sarscov
infect
similar
observ
respiratori
viru
infect
baa
et
al
rockx
et
al
signific
due
profibrot
natur
releas
tgfb
injur
tissu
promot
lung
repair
normal
lead
resolut
infect
sarscov
infect
often
lead
hyperactiv
tgfb
pathway
lead
promot
lung
fibrosi
anim
model
tgfb
regul
transgen
mice
overexpress
tgfb
show
produc
sever
pulmonari
fibrosi
mice
rat
sime
et
al
tgfb
activ
pathway
lead
product
fibrin
collagen
secret
proteas
matrix
metalloproteinas
tgfb
role
cellular
prolifer
investig
howev
evid
key
factor
epithelialemesenchym
transit
emt
seen
repair
tissu
tgfb
presenc
lung
requir
promot
lung
fibroblast
differenti
myofibroblast
import
repair
lung
tissu
howev
high
sustain
level
tgfb
persist
repair
process
result
damag
previous
publish
work
demonstr
infect
mous
adapt
strain
sarscov
call
signific
lung
damag
occur
infect
proce
later
time
point
develop
fibrosi
lung
infect
mice
transcriptom
analysi
lung
undergo
infect
found
signific
timedepend
upregul
sever
pathway
includ
macrophag
induct
chemokin
dysregul
compar
viral
lung
infect
induct
wound
heal
gene
analyz
wound
heal
pathway
led
egfr
protein
wound
heal
gene
regul
egfr
signal
werner
grose
suggest
egfr
signal
may
play
role
develop
fibrosi
sar
patient
egfr
name
human
epiderm
growth
factor
receptor
human
prototyp
member
famili
receptor
tyrosin
kinas
known
erbb
receptor
four
known
member
erbb
famili
three
jone
rappoport
ligand
bind
extracellular
domain
trigger
conform
chang
result
dimer
receptor
erbb
receptor
possess
intrins
tyrosin
kinas
activ
phosphoryl
specif
tyrosin
residu
cytoplasm
tail
phosphoryl
result
activ
signal
mapk
akt
jnk
pathway
yarden
shilo
yarden
sliwkowski
activ
egfr
signal
rang
outcom
inhibit
apoptosi
increas
cell
prolifer
migrat
activ
inflammatori
respons
increas
mucu
product
yarden
sliwkowski
egfr
express
tissu
deriv
epitheli
mesenchym
neuron
origin
yano
et
al
egfr
signal
especi
import
tissu
undergo
extens
turnov
cell
epitheli
layer
skin
lung
gut
egfr
activ
skin
keratinocyt
lead
cell
prolifer
migrat
cell
surviv
requir
wound
heal
lung
gut
egfr
signal
play
role
control
cell
turnov
mucu
product
role
egfr
well
studi
context
cancer
especi
nonsmal
cell
lung
cancer
mutat
egfr
routin
found
small
molecul
tyrosin
kinas
inhibitor
tki
like
gefitinib
afatinib
well
monoclon
antibodi
base
treatment
like
cetuximab
develop
chemotherapi
agent
inhibit
activ
egfr
kato
nishio
lenz
yano
et
al
howev
sinc
egfr
signal
also
regul
wound
heal
repair
normal
tissu
also
associ
fibrot
diseas
variou
organ
seven
known
identifi
ligand
egfr
schneider
wolf
fig
egf
transform
growth
factor
alpha
tgfa
amphiregulin
ar
epiregulin
ereg
heparin
bind
epiderm
growth
factor
hbegf
epitheli
mitogen
epigen
epgn
betacellulin
btc
egfr
ligand
express
transmembran
precursor
protein
cleav
cell
surfac
proteas
upon
injuri
anoth
signal
event
releas
extracellular
milieu
matur
protein
bind
extracellular
domain
egfr
structur
egfr
ligand
possess
least
one
egf
modul
fig
process
releas
disintegrin
metalloproteinas
adam
famili
metalloproteas
seal
courtneidg
solubl
fragment
contain
egf
modul
serv
activ
ligand
egfr
schneider
wolf
egf
nine
egf
modul
first
one
releas
serv
egfr
ligand
canon
ligand
singl
egf
modul
ctermin
tail
ligand
also
known
function
potenti
transcript
cofactor
transloc
nucleu
proteolyt
cleavag
kinugasa
et
al
nanba
et
al
polar
human
airway
epitheli
cell
ligand
express
proform
apic
membran
receptor
express
basolater
surfac
cell
vermeer
et
al
spatial
segreg
receptor
ligand
maintain
receptor
inact
state
homeostasi
upon
injuri
epitheli
barrier
compromis
allow
airway
surfac
liquid
asl
contain
small
amount
shed
ligand
contact
basolater
surfac
epithelium
activ
receptor
dempsey
et
al
vermeer
et
al
step
initi
wound
heal
respons
role
egfr
signal
fibrosi
develop
complex
evid
profibrot
antifibrot
role
egfr
signal
cancer
patient
treat
tyrosin
kinas
inhibitor
show
increas
incid
interstiti
lung
diseas
ild
often
precursor
pulmonari
fibrosi
kato
nishio
similar
associ
ild
also
seen
patient
treat
antiegfr
monoclon
antibodi
panitumumab
osawa
et
al
yamada
et
al
gefitinib
also
exacerb
pulmonari
fibrosi
induc
bleomycin
mice
suzuki
et
al
data
suggest
inhibit
egfr
signal
increas
risk
pulmonari
fibrosi
therefor
suggest
egfr
antifibrot
specif
context
howev
known
induc
fibrosi
studi
show
potent
induc
express
egfr
ligand
ar
silenc
ar
rnai
use
egfr
specif
small
molecul
inhibitor
gefitinib
attenu
fibrogen
effect
zhou
et
al
contrast
bleomycin
model
injuri
gefitinib
made
fibrosi
wors
suzuki
et
al
protect
mice
bleomycin
injuri
furthermor
mice
overexpress
egfr
ligand
tgfa
spontan
develop
lung
fibrosi
hardi
et
al
hardi
et
al
similar
effect
egfr
ligand
discuss
detail
section
studi
seem
indic
egfr
signal
profibrot
reconcil
seemingli
conflict
data
one
possibl
egfr
signal
differ
outcom
differ
speci
differ
fibrot
trigger
altern
possibl
fibrosi
may
result
dysregul
kinet
egfr
signal
rather
simpli
strength
signal
given
time
point
deposit
fibrot
materi
normal
compon
wound
heal
respons
unresolv
wound
heal
result
fibrot
diseas
adamson
et
al
bitterman
dysregul
control
either
upregul
egfr
signal
requir
initi
normal
wound
heal
downregul
egfr
signal
requir
resolut
wound
heal
process
could
result
fibrot
diseas
fig
role
egfr
fibrosi
progress
investig
use
vivo
model
primarili
mice
mice
lack
die
utero
miettinen
et
al
model
egfr
transgen
mice
overact
egfr
mutat
seen
human
cancer
made
demonstr
rapid
develop
lung
tumor
depend
egfr
signal
politi
et
al
mice
contain
egfr
mutat
lead
constitut
activ
mice
show
skin
relat
phenotyp
show
wavi
hair
thick
epidermi
fig
seven
known
ligand
egfr
membran
bound
inact
form
adam
famili
proteas
activ
respons
tissu
injuri
cleav
proligand
releas
egf
modul
contain
solubl
ligand
ligand
bind
receptor
caus
dimer
autophosphoryl
ctermin
tail
specif
tyrosin
residu
phosphoryl
activ
form
aggreg
sever
adaptor
protein
lead
activ
multipl
signal
cascad
rang
differ
outcom
produc
activ
pathway
list
schemat
fig
potenti
role
egfr
fibrosi
illustr
lung
exampl
physic
injuri
pathogen
initi
wound
heal
respons
damag
healthi
tissu
releas
egfr
ligand
activ
egfr
pathway
sustain
activ
egfr
pathway
result
exagger
wound
heal
respons
lead
fibrot
lung
earli
use
tyrosin
kinas
inhibitor
could
prevent
normal
progress
wound
heal
result
sustain
injuri
develop
fibrosi
altern
mechan
darken
pigment
fitch
et
al
mice
defici
tgfa
lack
egfr
signal
protect
chronic
lung
diseas
model
lung
damag
madt
et
al
final
bleomycin
induc
fibrosi
model
mice
tyrosin
kinas
inhibitor
gefitinib
abl
mitig
onset
fibrosi
ishii
et
al
littl
known
alter
egfr
signal
could
caus
pulmonari
fibrosi
viral
infect
howev
use
model
demonstr
egfr
regul
key
pathway
induct
damag
induc
pulmonari
fibrosi
major
canon
egfr
ligand
appear
play
role
promot
fibrosi
variou
organ
data
summar
tabl
data
show
constitut
ubiquit
express
egfr
ligand
result
constant
egfr
activ
result
activ
fibrosi
inhibit
egfr
signal
use
tki
coexpress
signal
defect
egfr
mutant
revers
onset
fibrosi
least
case
tgfa
overexpress
mice
hardi
et
al
hardi
et
al
use
tyrosin
kinas
inhibitor
like
erlotinib
famili
member
abl
revers
inhibit
fibrosi
develop
varieti
anim
model
tgfb
induct
hallmark
mani
fibrot
diseas
drive
express
egfr
ligand
lead
egfr
activ
modul
tgfb
signal
induct
activ
develop
upstream
tgfb
signal
sever
fda
approv
drug
losartan
pirfenidon
tranilast
effect
lower
tgfb
level
host
sever
small
molecul
antibodi
sirna
target
tgfb
current
clinic
trial
varieti
fibrot
cancer
relat
diseas
akhurst
hata
egfr
activ
induc
product
mucin
assist
clearanc
particl
debri
neutrophil
recruit
chemokin
addit
stimul
repair
inhibitor
either
overact
mucin
product
antagonist
could
use
modul
dysregul
egfr
respons
lead
resumpt
control
host
tissu
repair
caveat
use
tyrosin
kinas
inhibitor
specif
respect
pulmonari
toxic
use
gefitinib
report
induc
interstiti
lung
diseas
patient
treat
nonsmal
cell
lung
cancer
nsclc
kato
nishio
shi
et
al
tki
highli
effect
treat
egfr
posit
cancer
effect
normal
tissu
well
investig
develop
sever
lung
diseas
lead
pulmonari
fibrosi
sarscov
infect
major
complic
surviv
sarscov
outbreak
current
research
focus
wound
heal
pathway
mediat
tissu
repair
injuri
specif
egfr
pathway
specif
studi
dysregul
egfr
pathway
could
lead
develop
pulmonari
fibrosi
anim
model
sarscov
hypothes
target
inhibit
egfr
protein
activ
egfr
protein
downstream
egfr
signal
could
provid
novel
therapeut
intervent
pulmonari
fibrosi
patient
addit
believ
infect
highli
pathogen
respiratori
virus
like
merscov
futur
emerg
respiratori
virus
could
induc
pulmonari
fibrosi
patient
understand
egfr
wound
heal
profibrot
pathway
act
viral
infect
lead
novel
therapeut
futur
tabl
sever
group
construct
transgen
mice
express
known
egfr
ligand
mice
viabl
show
differ
fibrosisrel
phenotyp
summar
knockout
mice
mostli
viabl
except
case
hbegf
knockout
show
increas
resist
fibrosi
case
tgfa
ar
increas
sensit
fibrosi
hbegfbtc
doubleknockout
phenotyp
transgen
overexpress
model
phenotyp
knockout
mice
betacellulin
btc
increas
postnat
mortal
due
lung
patholog
schneider
et
al
btcknockout
mice
show
phenotyp
btchbegf
doubleknockout
show
cardiac
fibrosi
jackson
et
al
epiderm
growth
factor
egf
defect
growth
spermatogenesi
wong
et
al
fibrot
defect
report
fibrosisrel
phenotyp
report
factor
alpha
tgfa
spontan
fibrosi
week
birth
hardi
et
al
resist
bleomycininduc
fibrosi
madt
et
al
heparin
bind
epiderm
growth
factor
hbegf
pancrea
specif
overexpress
result
pancreat
fibrosi
mean
et
al
ko
mice
die
shortli
birth
btchbegf
doubleknockout
show
cardiac
fibrosi
jackson
et
al
hbegf
condit
knockoutinduc
liver
fibrosi
bile
duct
ligat
model
takemura
et
al
amphiregulin
ar
pancrea
specif
overexpress
result
pancreat
fibrosi
wagner
et
al
role
liver
fibrosi
perugorria
et
al
knockout
mice
significantli
resist
bleomycininduc
lung
fibrosi
ding
et
al
epiregulin
ereg
overexpress
model
role
fibrosi
report
phenotyp
fibrosi
report
lee
et
al
epigen
epgn
fibrosi
nerv
neurolog
defect
dahlhoff
et
al
phenotyp
fibrosi
report
dahlhoff
et
al
